Cambridge Healthtech Institute ’s 5th Annual

Cell Therapy Manufacturing

Commercializing Cell-Based Therapies

August 15-16, 2018


The recent approvals of CAR T therapies Yescarta and Kymiriah represent a major breakthrough for the cell therapy industry. But how will we manufacture these products at scale? And what platforms, technologies and cell processes can we expect to see in the future? Do the answers lie in traditional biomanufacturing methods or custom made processes?

CHI’s Cell Therapy Manufacturing meeting takes an in-depth look at the practical challenges of manufacturing autologous and allogenic cell therapies at scale, with dedicated sessions on cell processing, scalability, bioreactors, next-generation production technologies, automation, closed systems, supply chain and facility design. The meeting will feature extensive sessions on CAR-Ts, NK cells, TCRs and manufacturing CRISPR-based CAR Ts at scale.   


Preliminary Agenda


REDUCING COST OF GOODS

Manufacturing Complex Therapies - In-House, Outside or a Mix?

Devyn Smith, PhD, Chief Strategy Officer, Strategy & Ops, Sigilon

Taking the Decision to Manufacture In-House

Knut Niss, PhD, Vice President, Program Management, Mustang Bio


SCALING UP CAR T, CRISPR-BASED PRODUCTS AND OTHER ADOPTIVE T CELL THERAPIES

Development of the Manufacturing Process of CAR T Cell Therapies

Przemyslaw Kruczek, PhD, Senior Scientist, Autolus

Scalability Challenges with Molecular Switch Technologies for CAR T

Alan Smith, PhD, Executive Vice President, Technical Operations, Bellicum

Optimized Manufacturing SPEAR TCR T Cell Therapy for Solid Tumors

Mark Dudley, PhD, Senior Vice President, Bioprocessing & Development CMC, Technical Operations, Adaptimmune

Manufacturing Strategy for Chemotherapy-Resistant γδ T Cells for Treatment of Glioblastoma

Lawrence Lamb, PhD, Clinical Laboratory Immunologist, Professor of Medicine, The University of Alabama at Birmingham

Scaling Up Cell-Based Therapies

Ravinder Bhatia, PhD, Director, Pharmaceutical Development and Manufacturing Sciences, Johnson & Johnson


AUTOMATION AND REAL TIME PROCESS CONTROL

Automating Cell Therapy Manufacturing

Ohad Karnieli, PhD, MBA, CEO and Co-Founder, Atvio Biotech Ltd.; Chair, Process and Product Development Subcommittee, International Society of Cellular Therapies

Application of Biosensors Technologies for Real Time Process Control

Damian Marshall, PhD, Head, Analytical Development, Non-Clinical Operations, Cell & Gene Therapy Catapult UK




For more details on the conference, please contact:
Daniel Barry
Senior Conference Director
Cambridge Healthtech Institute
Phone: 781-247-6266
Email: dbarry@healthtech.com


For partnering and sponsorship information, please contact:

Companies A-K

Sherry Johnson
Senior Business Development Manager
Cambridge Healthtech Institute
Phone: 781-972-1359
Email: sjohnson@healthtech.com

Companies L-Z

Carolyn Benton
Business Development Manager
Cambridge Healthtech Institute
Phone: 781-972-5412
Email: cbenton@healthtech.com


Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  

Premier Sponsors:

Millipore Sigma
Unchained Labs